A Phase 1 Study To Estimate The Effects Of PD 0332334 On Lithium Pharmacokinetics In Healthy Subjects

Back to Search Print Save as PDF Bookmark Trial

NCT00820794

Last updated on March 14, 2019

Back to Search Print Save as PDF Bookmark Trial

About this Study

The purpose of this study is to investigate if PD 0332334 affects the pharmacokinetics of lithium by co-administering both drugs to healthy adults.

Study Location

Contact

1-800-718-1021

[email protected]

Eligibility criteria

Condition

Generalized Anxiety Disease

Sex

Females and Males

Age

21-55 years

Inclusion criteria

Show details

- Healthy males and/or females

- Age from 21 to 55 (inclusive)

- BMI ranges from 18 to 30 kg/m2

Exclusion criteria

Show details

- Previous participation in a PD 332334 study

- Pregnant or nursing females

- Hypersensitivity (allergic) to lithium, Neurontin (gabapentin), or Lyrica (pregabalin)

NCT00820794

Pfizer

Withdrawn

A Phase 1 Study To Estimate The Effects Of PD 0332334 On Lithium Pharmacokinetics In Healthy Subjects

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now email

Based on your search, you may also be interested in

Generalized Anxiety Disease

A Phase 1 Study To Estimate The Effects Of PD 0332334 On Lithium Pharmacokinetics In Healthy Subjects

NCT00820794

All Genders

Hot Topics

You are here

A Phase 1 Study To Estimate The Effects Of PD 0332334 On Lithium Pharmacokinetics In Healthy Subjects

NCT00820794

About this Study

NEED INFO?

Try a new search

Based on your search, you may also be interested in

Hot Topics

You are here

A Phase 1 Study To Estimate The Effects Of PD 0332334 On Lithium Pharmacokinetics In Healthy Subjects

NCT00820794

About this Study

NEED INFO?

Try a new search

Based on your search, you may also be interested in

FOR MORE INFORMATION